1mg is India’s leading consumer health platform with over 5.5 Million downloads and 75M annual visits. It aspires to be the trusted health partner for all Indians and its mission is to make healthcare accessible, understandable and affordable for a billion Indians. It enables consumers to learn more about their medicines and also find more cost-effective substitutes.
AAA is a leading European company which markets and sells products in the area of radioimaging and radiopharmaceuticals. It is a unique platform of laboratories, production centers, research, development, production and distribution for radio molecular diagnostics across Europe. It is pioneering development of first in class radiopharmaceuticals for the regulated markets.
APR is a pharma company developing and out-licensing new drugs and new drug formulations for a variety of applications based on the company’s science driven formulation technology and expertise. These technologies include orally dispersible and disintegrating films. Application areas include Rx products as well as OTC products.
ARMO BioSciences is a clinical stage developer of immuno-therapeutics focused on the oncology space and is anchored by its platform molecule AM0010, a PEGylated form of recombinant human IL-10. The company has a unique approach to developing therapeutic cytokines that are complimentary to other immune-oncology therapeutics and standard of care drugs.
Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company has developed a CE certified implant to treat cluster headache which is commercially available in Europe.
BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for biopharma companies and research institutions.
Basilea Pharmaceutica is listed on the SIX Swiss Exchange (SIX:BSLN). The company sells and develops innovative antibiotics, antifungals and oncology drugs.
BioControl Medical develops implantable medical devices to treat disorders of the autonomic nervous system. BioControl Medical has focused on the development of the CardioFit® System for the treatment of heart failure via direct vagus nerve stimulation.
CardiacAssist is selling the TandemHeart Pump an implantable circulatory support device to support patients with severe cardiac dysfunction. More than 3,000 patients have been treated with the TandemHeart.
Cathay Industrial Biotech is the world leader in the production of long chain dibasic acids used primarily for nylons, polyesters and adhesives and bio-solvents. Cathay’s leading-edge technology allow the manufacturing of chemicals and fuels from renewable resources.
Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. Curetis’ Unyvero System enables rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours.
Eiger is a clinical-stage company with four programs addressing orphan diseases with a high unmet medical need. Lonafarnib, a Phase 2 stage farnesyl inhibitor is being developed for HDV, the deadliest form of viral hepatitis. Other programs include therapies for hyperinsulinemic hypoglycemia following bariatric surgery, PAH and lymphedema.
Ellipse Technologies designs, develops and commercializes non-invasively adjustable remote controlled implants for a broad spectrum of spinal and othopedic applications. Ellipse products aid to restore proper anatomic position and aligemnt of the spine and correct limb length discrepancies.
Gynesonics focuses on the incision-less therapy of symptomatic uterine fibroids, the most common benign tumors in women. Gynesonics has developed VizAblate®, a transcervical, ultrasound-guided ablation system which has a CE Mark in the European Union.
he EasyScan scanning laser ophthalmoscope offers a dilation-free 3-minute retinal exam for the early detection of diseases such as diabetic retinopathy. The Cassini color LED topographer provides a highly precise 3-dimensional map of the cornea, supporting e.g. cataract surgery planning and determination of IOL implants.
Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines for serious diseases. The company’s expertise in the role of Tissue Factor (TF) in angiogenesis, inflammation, and metastasis has allowed us to develop a unique therapeutic approach to retinal disease and cancer.
Interventional Spine designs, develops and markets patented implantable devices for the spine that can be deployed via percutaneous techniques.
Kolltan Pharmaceuticals, Inc. is developing novel monoclonal antibody drugs targeting receptor tyrosine kinases (RTKs).
Lipid Therapeutics GmbH is developing novel therapies for inflammatory diseases of the digestive system. The company's current focus is to develop LT-02, a delayed release of Phosphatidylcholine, for the treatment of Ulcerative colitis. LT-02 is currently in PhIII clinical development.
MiCardia is marketing its enCorSQ Mitral Valve Repair System, in the Europe. The enCorSQ device allows the surgeon to address any recurrent MR or coaptation correction, real-time, off-pump, on a beating heart, days or months after the surgical implant.
Nabriva Therapeutics is developing pleuromutilin antibiotics, a new class of antibacterial compounds, for the treatment of serious infections in humans caused by multi-drug resistant pathogens.
Neurelis, Inc. is a specialty pharmaceutical company organized to license, develop, and commercialize product candidates for the treatment of central nervous system disorders with a focus on the treatment of acute breakthrough seizures (epilepsy) and acute anxiety episodes.
ObsEva is a biopharmaceutical company addressing important unmet needs in women’s health, including premature labor, infertility and endometriosis. ObsEva’s pipeline comprises a number of orally active small molecules addressing both validated and novel targets.
Ophthotech (NASDAQ: OPHT) develops novel therapies for the treatment of diseases of the eye. Ophthotech specializes in innovative treatment strategies for wet age-related macular degeneration (AMD), the leading cause of vision loss in people over the age of 55.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients.
Paratek’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians.
Probiodrug focuses on the discovery and development of new Alzheimer’s drugs.
PTC Therapeutics (NASDAQ: PTCT) develops orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Ataluren (brand name: Translarna) received conditional marketing authorization from European Medicines Agency (EMA) for the treatment of nmDMD.
Reha Technology produces and sells robotic systems for the rehabilitation of stroke patients. Reha’s G EO System helps patients to walk again, and to re-learn climbing stairs. Other robotic systems are shortly before the market launch.
SAI Life Sciences delivers advanced Discovery, Contract Development and Manufacturing Solutions, through a broad suite of expert capabilities across the molecular life cycle, exclusively for Pharma innovators.
Skyepharma (LSE: SKP) specialises in oral and inhalation drug delivery technologies. Skyepharma’s track record includes successful development of both dry powder inhalers (DPIs) and metered dose inhalers (MDIs) with products achieving approvals in over 30 countries worldwide. Oral products using Skyepharma technologies have achieved in-market sales of approximately US$4bn over the last 5 years.
Symbiomix is a biopharmaceutical company with a focus on women’s health. The company’s lead product, SYM-1219, is a new anti-infective drug being studied as the first oral one-and-done treatment in the United States for bacterial vaginosis (BV), a common but underappreciated gynecological infection that greatly increases the risk of serious health problems.
Tensys Medical, Inc. is dedicated to improving patient safety by designing, manufacturing and marketing a continuous, non-invasive blood pressure monitoring system. Tensys’ T-Line allows early recognition and treatment of rapid changes in blood pressure in the OR and improves diagnosis and management of cardiovascular conditions in non-surgical settings.
True North has a robust product engine capable of generating a proprietary pipeline of novel monoclonal antibodies to treat rare diseases. Our most advanced product candidate, TNT009, is a first-in-class, anti-C1s antibody that selectively targets the classical pathway of the complement system. This novel antibody is currently in clinical development for the treatment of rare diseases in hematology, transplantation, and dermatology.
Westmed designs, manufactures and markets leading quality medical devices for anesthesia and respiratory applications. Westmed employs over 500 people worldwide and has manufacturing facilities in Arizona and Mexico.
© HBM Partners AG